domingo, 29 de septiembre de 2024

FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC Sharon Worcester, MA September 27, 2024

https://www.medscape.com/viewarticle/fda-okays-osimertinib-after-crt-locally-advanced-2024a1000hjd

No hay comentarios:

Publicar un comentario